Results 221 to 230 of about 2,009,855 (385)

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells

, 1989
Mary L. Stracke, Jason D. Engel, Lori W. Wilson, Matthew M. Rechler, Lance A. Liotta, E Schiffmann   +5 more
openalex   +1 more source

Neurobiology of COVID-19-Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling. [PDF]

Neuropsychopharmacol Rep
Nawa H, Murakami M.
europepmc   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class. [PDF]

, 1988
R G Gronwald, Francis James Grant, Betty Haldeman, Charles E. Hart, Patrick J. O’Hara, F S Hagen, Russell Ross, Daniel F. Bowen‐Pope, Mark J. Murray   +8 more
openalex   +1 more source

Cell Adhesion Molecules as Modulators of the Epidermal Growth Factor Receptor. [PDF]

Cells
Kozlova I, Sytnyk V.
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha.

, 1988
Irit Lax, Ann Johnson, R. Howk, John Sap, F. Bellot, M. Winkler, A Ullrich, Björn Vennström, Joseph Schlessinger, David Givol   +9 more
openalex   +1 more source

Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition. [PDF]

, 1985
Alain B. Schreiber, J. Kenney, W. Kowalski, Robert Friesel, Tevie Mehlman, T Maciag   +5 more
openalex   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source